Tredegar Corporation 2010 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2010. Tredegar Corporation is a manufacturer of plastic films and aluminum extrusions. The company operates through three primary segments: Film Products (personal care, protective, and packaging films), Aluminum Extrusions (building and construction, transportation, and industrial markets), and Other (start-up operations including Bright View Technologies and Falling Springs mitigation banks). The company employs approximately 2,000 people and operates facilities in the U.S., Europe, Asia, and South America.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Net Sales | $740.5 million | $648.6 million |
| Net Income | $27.0 million | ($1.4 million) loss |
| Diluted EPS | $0.83 | ($0.04) |
| Operating Cash Flow | $46.4 million | $103.2 million |
| Capital Expenditures | $20.4 million | $34.1 million |
| Total Debt | $0.45 million | $1.16 million |
| Cash and Equivalents | $73.2 million | $90.7 million |
| Shareholders' Equity | $417.5 million | $429.1 million |
Margins: Consolidated gross profit margin was 17.1% in 2010, down from 17.8% in 2009. The effective tax rate was 33.7% in 2010 compared to 107.8% in 2009 (the latter year was impacted by a significant goodwill impairment charge).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14.2% year-over-year, driven by higher volumes in both Film Products (+14.4%) and Aluminum Extrusions (+12.5%).
- Profitability Turnaround: The company returned to profitability with $27.0 million in net income, reversing a $1.4 million loss in 2009. This improvement was aided by the absence of the $30.6 million goodwill impairment charge recorded in the Aluminum Extrusions segment in 2009.
- Segment Performance:
- Film Products: Operating profit from ongoing operations rose to $71.2 million (from $64.4 million), supported by volume growth and price increases, though partially offset by a lag in passing through higher resin costs.
- Aluminum Extrusions: Operating loss from ongoing operations narrowed to $4.2 million (from $6.5 million) due to volume recovery and cost controls, though the segment remains challenged by the nonresidential construction market.
- Other: This new segment incurred an operating loss of $4.2 million in 2010 due to start-up costs for Bright View and Falling Springs.
- Investment Volatility: The company recognized a $2.2 million unrealized loss on a privately held specialty pharmaceutical investment in 2010, compared to a $5.1 million gain in 2009.
Guidance, Outlook, and Risks
- Outlook: Management projects 2011 capital expenditures of approximately $37 million ($27 million for Film Products, $5 million for Aluminum Extrusions). Depreciation is expected to rise slightly in 2011.
- Customer Concentration: The Procter & Gamble Company (P&G) remains the largest customer, accounting for approximately 38% of consolidated net sales in 2010. Loss of this customer would have a material adverse effect.
- Raw Material Volatility: Profitability is sensitive to the costs of resin (Film Products) and aluminum/energy (Aluminum Extrusions). While the company utilizes pass-through mechanisms, there is a lag (approx. 90 days) that can compress margins during periods of rising input costs.
- Construction Sector: The Aluminum Extrusions segment remains highly dependent on the U.S. nonresidential construction market, which faces uncertainty regarding the timing and extent of recovery.
- Debt Covenants: The company has a $300 million revolving credit facility with no outstanding borrowings as of year-end. However, noncompliance with covenants could restrict liquidity.
Investor Verification Checklist
- P&G Dependency: Verify the stability of the relationship with P&G and any potential shifts in their sourcing strategies.
- Resin Cost Pass-Through: Monitor the timing lag between resin price increases and price adjustments passed to customers, as this directly impacts Film Products margins.
- Pharmaceutical Investment: Review the status of the privately held pharmaceutical investment (carrying value $16.0 million) and the likelihood of future write-downs or write-ups based on FDA approval timelines.
- Construction Recovery: Assess indicators for the U.S. nonresidential construction market to gauge the sustainability of the Aluminum Extrusions segment's volume recovery.
- Working Capital: Note the significant increase in inventories ($7.5 million) and accounts receivable ($10.1 million) in 2010, which contributed to the decrease in operating cash flow despite higher net income.